Pfizer Inc (NYSE: PFE) has reported E.P.S. of $0.55 for its first fiscal quarter (ending March 31) versus $0.98 for the same period a year ago — a decline of -44%. This performance was $-0.15 short of the consensus estimate of $0.70. E.P.S. were $-0.05 for the latest four quarters through March 31 versus $5.17 for the same period a year ago — a decline of -101%.
Recent Price Action
Pfizer Inc (NYSE: PFE) stock enjoyed a very large increase of 6.1% on 5/1/24. The shares closed at $27.18. Moreover, trading volume in this advance was exceptionally high at 230% of normal. Relative to the market the stock has been extremely weak over the last nine months but has risen 3.3% during the last week.
Current PriceTarget Research Rating
PFE is expected to continue to be a major Value Builder reflecting capital returns that are forecasted to exceed the cost of capital.
Pfizer has a current Value Trend Rating of C (Low Neutral). This rating combines very contradictory signals from two proprietary PTR measures of a stock’s attractiveness. Pfizer has a good Appreciation Score of 78 but a very low Power Rating of 12, leading to the Low Neutral Value Trend Rating.
Rating Review
In light of this discouraging new earnings information we are reviewing our current Overall Rating of C. This review will be completed in the next several days.
Be the first to comment